Next Article in Journal
Exploration of Deregulated Long Non-Coding RNAs in Association with Hepatocarcinogenesis and Survival
Previous Article in Journal
MicroRNA Polymorphisms in Cancer: A Literature Analysis
Previous Article in Special Issue
Complications from Stereotactic Body Radiotherapy for Lung Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(3), 1815-1846; doi:10.3390/cancers7030864

The Evolution of Therapies in Non-Small Cell Lung Cancer

1,2,* , 1,2,†
,
2,3,4,5,†
and
1,2,†
1
Department of Medical Oncology, Monash Medical Centre, 823-865 Centre Road, East Bentleigh VIC 3165, Australia
2
Hudson Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton VIC 3168, Australia
3
Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia
4
UNSW Faculty of Medicine, St Vincent's Clinical School, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia
5
Department of Thoracic Medicine, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia:
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Siow Ming Lee
Received: 6 July 2015 / Revised: 3 September 2015 / Accepted: 7 September 2015 / Published: 9 September 2015
(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
View Full-Text   |   Download PDF [709 KB, uploaded 9 September 2015]   |  

Abstract

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver mutations has led to new ways in classifying NSCLC as well as offered novel therapeutic targets for anticancer therapy. Targets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with appropriate tyrosine kinase inhibitors (TKIs). Other driver mutations such as ROS, MET, RET, BRAF have also been investigated with targeted agents with some success in the early phase clinical setting. Novel strategies in the field of immune-oncology have also led to the development of inhibitors of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 receptor (PD-1), which are important pathways in allowing cancer cells to escape detection by the immune system. These inhibitors have been successfully tried in NSCLC and also now bring the exciting possibility of long term responses in advanced NSCLC. In this review recent data on novel targets and therapeutic strategies and their future prospects are discussed. View Full-Text
Keywords: non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); tyrosine kinase inhibitors; immuno-oncology; cytotoxic T lymphocyte antigen-4 (CTLA-4); programmed death-1 receptor (PD-1); PD-1 inhibitors non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); tyrosine kinase inhibitors; immuno-oncology; cytotoxic T lymphocyte antigen-4 (CTLA-4); programmed death-1 receptor (PD-1); PD-1 inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boolell, V.; Alamgeer, M.; Watkins, D.N.; Ganju, V. The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers 2015, 7, 1815-1846.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top